[1] Kademani D. Oral cancer [J]. Mayo Clin Proc, 2007, 82(7): 878-887. [2] Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Can J Clin, 2005, 55(2): 74-108. [3] Prgomet Z, Axelsson L, Lindberg P, et al. Migration and invasion of oral squamous carcinoma cells is promoted by WNT5A, a regulator of cancer progression [J]. J Oral Pathol Med, 2015, 44 (10): 776-784. [4] Zhou JP, Gao ZL, Zhou ML, et al. Snail interacts with Id2 in the regulation of TNF-alpha-induced cancer cell invasion and migration in OSCC [J]. Am J Cancer Res, 2015, 5(5): 1680-1691. [5] Kim NG, Koh E, Chen X, et al. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components [J]. Proc Natl Acad Sci USA, 2011, 108(29): 11930-11935. [6] Zhao B, Li L, Wang L, et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis [J]. Genes Dev,2012, 26(1): 54-68. [7] Wada K, Itoga K, Okano T, et al. Hippo pathway regulation by cell morphology and stress fibers [J]. Development, 2011,138(18): 3907-3914. [8] Dupont S, Morsut L, Aragona M, et al. Role of YAP/TAZ in mechanotransduction [J]. Nature, 2011, 474(7350): 179-183. [9] Lai ZC, Wei X, Shimizu T, et al. Control of cell proliferation and apoptosis by mob as tumor suppressor, mats [J]. Cell, 2005, 120(5): 675-685. [10] Harvey K, Tapon N. The Salvador-Warts-Hippo pathway-an emerging tumour-suppressor network [J]. Nat Rev Cancer, 2007, 7(3): 182-191. [11] Camargo FD, Gokhale S, Johnnidis JB, et al. YAP1 increases organ size and expands undifferentiated progenitor cells [J]. Curr Biol,2007,17(23): 2054-2060. [12] Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals [J]. Cell, 2007, 130(6): 1120-1133. [13] Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon [J]. Proc Natl Acad Sci USA,2006,103(33): 12405-12410. [14] Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma [J]. Cancer, 2009, 115(19): 4576-4585. [15] Zhang J, Ji JY, Yu M, et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway [J]. Nat Cell Biol, 2009, 11(12): 1444-1450. [16] Hamaratoglu F, Gajewski K, Sansores-Garcia L, et al. The Hippo tumor-suppressor pathway regulates apical-domain size in parallel to tissue growth [J]. J Cell Sci, 2009, 122(Pt 14): 2351-2359. [17] Ge L, Smail M, Meng W, et al. Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis [J]. PLoS One, 2011, 6(11): e27529. [18] Zhang L, Pan HY, Zhong LP, et al. Fos related activator-1 is overexpressed in oral squamous cell carcinoma and associated with tumor lymph node metastasis[J]. J Oral Pathol Med, 2010, 39(6): 470-476. [19] Sobin LH, Wittekind CH. International Union Against Cancer (UICC). TNM classification of malignant tumours[M]. 6th Ed. New York: Wiley-Liss, 2002. [20] Zhang L, Ye DX, Pan HY, et al. Yes-associated protein promotes cell proliferation by activating Fos related activator-1 in oral squamous cell carcinoma [J]. Oral Oncol, 2011, 47(8): 693-697. [21] Huntoon CJ, Nye MD, Geng L, et al. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway [J]. Cancer Res, 2010, 70(21): 8642-8650. [22] Wang Y, Dong Q, Zhang Q, et al. Overexpression of yesassociated protein contributes to progression and poor prognosis of non-smallcell lung cancer [J]. Cancer Sci, 2010, 101(5): 1279-1285. [23] Da CL, Xin Y, Zhao J, et al. Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions [J]. World J Gastroenterol, 2009, 15(32): 4055-4061. [24] Roperch JP, El Ouadrani K, Hendrix A, et al. Netrin-1 induces apoptosis in human cervical tumor cells via the TAp73alpha tumor suppressor [J]. Cancer Res,2008,68(20): 8231-8239. [25] Tomlins SA, Chinnaiyan AM. Of mice and men: cancer gene discovery using comparative oncogenomics[J]. Cancer Cell, 2006, 10(1): 2-4. [26] Avruch J, Zhou D, Fitamant J, et al. Mst1/2 signalling toYap: gatekeeper for liver size and tumour development [J]. Br J Cancer, 2011, 104(1): 24-32. [27] Muramatsu T, Imoto I, Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma [J]. Carcinogenesis, 2011, 32(2): 389-398. [28] Zhang X, George J, Deb S, et al. The Hippo pathway transcriptional coactivator, YAP, is an ovarian cancer oncogene [J]. Oncogene,2011, 30(25): 2810-2822. [29] Lamar JM, Stern P, Liu H, et al. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain[J]. Proc Natl Acad Sci USA,2012,109(37): E2441-2450. [30] Ehsanian R, Brown M, Lu H, et al.YAP dysregulation by phosphorylation or ΔNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets [J]. Oncogene, 2010, 29(46): 6160-6171. |